Divestco Appoints CFO

Calgary, Alberta–(Newsfile Corp. – December 13, 2018) – Divestco Inc. (TSXV: DVT) (“Divestco” or the “Company”) is pleased to announce the appointment of Ruth Summers as CFO effective December 1, 2018. Ms. Summers brings over 20 years of financial advisory and capital markets experience in a variety of sectors including upstream and midstream oil and gas, power generation, public infrastructure and alternative energy.

Ms. Summers was most recently working for a public oil and gas company in treasury and strategy.  She has extensive experience in acquisitions and divestitures, capital raising (debt and equity), strategic planning and risk analysis.

Mr. Stephen Popadynetz remains President and CEO of Divestco. Mr. Popadynetz commented, “We are very fortunate to have an extremely qualified Board member in Ruth Summers assume the role of CFO at Divestco.  I have known Ruth for several years now and our shareholders and investors can rest easy that our company will be receiving top tier leadership and direction and that in her previous roles she has helped companies access capital and initiate growth.  With the challenges in our economy and the scarcity of capital out there, we couldn’t have had a more suited or skilled individual join our executive team to help us transition into a stable a viable corporation.”

About the Company

Divestco provides innovative geoscience solutions to Energy and Service companies worldwide. Our customers predominantly operate in geology, geophysics, land and engineering and we work with our clients to ensure they have the right solutions, at the right time, to help them make more informed decisions. Commitment, innovation, accountability and agility form the cornerstone of our values and enable us to consistently provide reliable solutions and exceptional, personalized service in all of the core areas in which we operate. Divestco provides Software & Data, Seismic Processing, Geomatics Services, Seismic Data & Brokerage, and Land Services. Divestco is headquartered in Calgary and trades on the TSX Venture Exchange under the symbol “DVT”.

For more information please contact:

Divestco Inc.
(www.divestco.com)

Mr. Stephen Popadynetz
CEO, President and CFO
Tel 587-952-8152

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Advertisements

Relay Medical Appoints Executives; John Soloninka Appointed Senior Vice-President, Acquisitions and Exits; Yoav Raiter as Director, Product Development

Toronto, Ontario–(Newsfile Corp. – December 13, 2018) – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company“), an engine of MedTech innovation, is pleased to announce the appointment of John Soloninka as Senior Vice-President of Acquisitions and Exits and Yoav Raiter as Director of Product Development. The appointments have been made in support of the Company’s multi-project integrated accelerator model.

John Soloninka is a seasoned MedTech executive with over 25 years of experience in innovation, commercialization, health systems strategy consulting, business development and sales. As former CEO of an early stage venture debt fund and serial entrepreneur, John led diligence of over 300 companies, financed 40+ early-stage medical technology companies and raised venture and angel funds in Canada, the US and Europe. Along with business partners, John created, financed, operated, grew and divested companies in oncology, radiology, speciality pharma, SaaS EMR/clinical trials, pathology, diagnostics, and interventional radiology medical video education. John is experienced in driving clinical and technology research/product development and launch and managing complex long-close sales and strategic initiatives.

“John is an exceptional executive in the Medtech space with his breadth and depth of knowledge and his industry connections. His ability to build relationships, to dive deep in the heart of the matter, and to drive process is remarkable as is his ability to conduct creative innovation-conversations.” said Lahav Gil, CEO, Relay Medical Corp.

Yoav Raiter is a product development and innovation management veteran with over 20 years of experience leading the development of large-scale software teams, and 5 years in medical device development management. Yoav formerly worked with Canada’s largest contract medical devices development company StarFish Medical and prior to that led projects at Kangaroo Group for 3 years.

“Yoav’s attention to technical details as well as to business outcomes makes him a remarkable professional to work with. He has a unique style of leadership, which emphasises accountability and empowers the team, and is highly regarded by the clini-commercial team and the medtech community.” continued Lahav Gil, CEO, Relay Medical Corp.

Yoav and John’s appointments are effective immediately and both executives report directly to the CEO.

About John Soloninka

John graduated from Queen’s University in engineering physics in 1981 and worked several years in aerospace engineering before earning an MBA with distinction, from the University of London in England in 1986.

John has a deep understanding of health systems, reimbursement, health economics and regulatory processes. As a strategy consultant for IBM, Price Waterhouse and Accelerant Health Innovations, he led high impact health system transformation projects, consulted extensively to government and private sector clients and created and led large medical research coalitions in oncology, neuroscience and clinical trials. He understands the divergent needs of academic research, government and public institutions, start-ups, mid-sized private and public companies, including $100B globally-integrated companies with large R&D and patent portfolios.

As designated “Canadian Investment Champion”, John led inter-government and inter-company missions to the EU, USA, Israel, Japan, Singapore, Qatar, Dubai and China, resulting in joint ventures for R&D, commercialization, and “soft landing” market access partnerships in the US, UK, China and Switzerland. John was privileged to be an Expert Witness on Health Innovation for the Canadian Government’s House Standing Committee on Healthcare.

John has recently served on advisory boards and boards of directors for the Centre for Imaging Technology Commercialization (CIMTEC), the Ontario Brain Institute (OBI), HTX, MaRS EXCITE (Excellence in Clinical Innovation and Technology Evaluation), and Baycrest Centre/Rotman Research Institute. He was formerly Chair of the Rotman Research Institute’s Research Advisory Committee (RAC).

About Yoav Raiter

Yoav’s wide-spanning career has focused on developing innovative software and medical device products mainly for start-ups and fast-growing companies. Yoav developed processes to ensure delivery of clients needs at high quality, improved operations, and business strategy.

Prior to joining Relay Medical, Yoav was project manager for strategic accounts at StarFish Medical and Director of project management and business development at Kangaroo Group. Yoav has additionally held several prominent positions managing large scale ERP product development and implementation projects for broadcasters in Canada and the US for Pilat Media and SintecMedia.

Yoav was the co-founder and Co-CEO of Panta-Rhei, a software development and consulting firm. In this position Yoav lead the development of new products and has consulted and worked with a wide variety of companies as instructor for creative thinking methodologies where he helped organizations improve their processes and strategies.

Yoav received an MBA, Specialized in High Tech Innovation Strategy, from Haifa University in Israel and
B.Sc., Industrial Engineering, major: Project Management, Business Development and Information Systems from the Technion at Haifa, Israel.

The Company also announces that it has granted an aggregate of 2,733,000 options to purchase common shares of the Company exercisable at a price of $0.27 per share and expiring on December 13, 2023 to certain directors, officers and consultants of the Company.

About Relay Medical Corp.

Relay Medical is an evolving “Integrated MedTech Accelerator” headquartered in Toronto, Canada, acquiring early-stage technologies and inventions, advancing and preparing them for pre-commercial acquisitions in the HealthTech marketplace. By integrating the funding, development and exit process into one organization led and managed by one expert team, Relay Medical is building the capacity to accelerate and transact technologies with high efficiency and grow into a leading engine for MedTech innovation in the global HealthTech marketplace.

Website: www.relaymedical.com

Contact:
W. Clark Kent
President

Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@relaymedical.com

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for UXD described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com

CellCube Spinout Company V23 Resource Signs LOI with Regency Gold

Toronto, Ontario–(Newsfile Corp. – December 13, 2018) – CellCube Energy Storage Systems Inc. (CSE: CUBE) (OTCQB: CECBF) (FSE: 01X) (“CellCube” or the “Company”) is pleased to announce that its wholly owned subsidiary, V23 Resource Corp. (“V23 Resource”), has signed a non-binding letter of intent (“LOI”) with Regency Gold Corp., a TSX Venture Exchange company (TSXV: RAU.H.X), for the purpose of a business combination that would result in V23 Resource becoming a publicly listed company.

The LOI contemplates that the two companies will enter into a combination by way of a reverse merger or acquisition that will lead to V23 Resource becoming the resulting issuer on the TSX Venture Exchange. The companies will continue to negotiate and conduct due diligence and expect to enter into a definitive binding agreement within 30 days.

Spin-out and Distribution to Shareholders of V23 Resource Corp.

CellCube has established a record date of January 4, 2019, for the spin-out of its 100-per-cent-owned Bisoni Mackay and Bisoni-Rio vanadium assets into the newly formed V23 Resource (see news release dated June 28, 2018). CellCube shareholders of record owning common shares of the Company on January 4, 2019, will be eligible to receive the distribution of one common share of V23 Resource for every two common shares of CellCube upon completion of the spinout arrangement. CellCube intends to retain a 19.9-per-cent interest in V23 Resource, in addition to certain off-take rights, and the transaction is expected to be completed by year end.

“The spin-out of our vanadium assets into a new publicly listed entity will greatly enhance shareholder value,” stated Mike Neylan, CEO of CellCube. “With vanadium prices approaching unprecedented levels, this is a critical step to unlock the value of our resource business for the benefit of our current shareholders,” further commented Mr. Neylan.

V23 Resource Corp.

V23 Resource Corp. is a vanadium exploration company wholly owned by CellCube, with two vanadium properties located in Nye County, Nevada. CellCube’s Bisoni McKay and Bisoni-Rio properties represent a significant pure play vanadium projects in North America, totalling 4,115 acres contiguous to the Gibellini deposit held by Prophecy Development Corp.

Drilling of 52 drill holes and exploration to date have indicated that the Bisoni McKay is a pure play vanadium resource that does not possess any significant concentrations of any secondary metals. Of greater importance, only 12 per cent of the Bisoni McKay area has been drilled (and none of the Bisoni-Rio), which has already resulted in the estimation of a National Instrument 43-101 indicated resource of 11.9 million tons at an average grade of 0.39 per cent vanadium pentoxide (“V2O5”), and an inferred resource of 7.0 million tons at an average grade of 0.42 per cent V2O5 (see news release dated September 13, 2016). The indicated resource is contained in a zone approximately 300 metres in strike length, while the inferred resource covers approximately an additional 200 metres of strike length extending to the south. The mineralized zone appears to be open at depth and extends to the north into the Bisoni-Rio property. In 2017, CellCube staked 162 claims on the Bisoni-Rio property from the Bisoni McKay right up to and abutting the Gibellini vanadium property owned by Prophecy Development Corp. (see company news release dated June 28, 2018).

Chris M. Healey, P.Geo, geological consultant to CellCube, is the independent qualified person who has reviewed and approved the scientific and technical contents of this press release.

About CellCube Energy Storage Systems Inc.

CellCube is a Canadian public company listed on the Canadian Securities Exchange (symbol CUBE), the OTCBB (symbol CECBF), and the Frankfurt Exchange (Symbol 01X WKN A2JMGP) focused on the fast-growing energy storage industry which is driven by the large increase in demand for renewable energy.

CellCube supplies vertically integrated energy storage systems to the power industry and recently acquired the assets of Gildemeister Energy Storage GmbH, now Enerox GmbH the developer and manufacturer of CellCube energy storage systems. CellCube recently acquired EnerCube Switchgear Systems (formerly Jet Power and Controls Ltd.) and Power Haz Energy Mobile Solutions Inc. (formerly HillCroft Consulting Ltd.) and has also invested in an online renewable energy financing platform, Braggawatt Energy Inc.

CellCube develops, manufactures, and markets energy storage systems on the basis of vanadium redox flow technology and has over 130 project installations and a 10 year operational track record. Its highly integrated energy storage System solutions features 99% residual energy capacity after 11,000 cycles with the focus on larger scale containerized modules. Basic building blocks consist of a 250kW unit family with 4, 6 and 8 hours variation in energy capacity.

On Behalf of CellCube Energy Storage Systems Inc.,
Mike Neylan, CEO, Director

Glenda Kelly, Investor Communications
1 800 882-3213
Email: info@cellcubeenergystorage.com
www.cellcubeenergystorage.com

This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts which address events, results, outcomes or developments that the Company expects to occur; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Certain material assumptions regarding such forward-looking statements are discussed in this news release and the Company’s annual and quarterly management’s discussion and analysis filed at www.sedar.com. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

New NUGL Ad Program a Catalyst to Cannabis Company Sales Efforts

Los Angeles, California–(Newsfile Corp. – December 13, 2018) – NUGL Inc. (OTC: NUGL) (the “Company”), the cannabis industry’s new standard of technology, is pleased to announce the complete roll-out of its robust advertising program across the universe of all NUGL owned media outlets. The final integration represents the completion of a lengthy period of proprietary strategy and design to create an offering perfectly tailored to cannabis-based businesses.

NUGL has been selling revenue generating advertising into all digital platforms such as NUGL.com, the iOS Apple NUGL APP and Android Applications. In addition, advertising revenue is being generated on all three digital magazines and two print publications.

Additionally, the Company is pleased to report that user sign-ups, profile sign-ups, and menu item offerings greatly accelerated after a relatively small “test” marketing spend. These are business sign-ups and the reaction relative to the expenditure is assuring, especially so with regard to the menu sign-ups which are genuine engagement activity AFTER the user has been driven to NUGL’s interface.

“Our sales staff are excited as we have so much to offer to our clients in the form of advertising opportunities,” said Bob Waters, VP of Sales, NUGL, Inc. “NUGL doesn’t just offer ad placement, we combine the software, digital and print media to give cannabis companies the ability to attract new clients at a fair price for the first time in the industry.”

NUGL has recently acquired top industry publications and continues to expand the reach and feature base of its software. “Our blueprint for marketing is to integrate our ad programs with our sales staff sales in perfect harmony. We intend to continue to grow our user base and our profile base while creating new and exciting marketing opportunities for our clients. We have the formula and now can see our growth minute by minute,” said Ryan Bartlette, CMO, NUGL. “With the increase in revenue, and now improved infrastructure and staff, we have even more resources than before to support the community and plan to do it better and faster.”

About NUGL

NUGL is the world’s first cannabis search app built for the people, by the people. Our goal is to build the most user-friendly app experience in the cannabis industry by listening to our users and giving them what they want. NUGL is the only cannabis search app that offers equal and unbiased search results. We don’t sell top-spot listings or fake reviews, so our data stays true. Use NUGL to search for genuine user-rated dispensaries, strains, doctors, lawyers, cannabis service providers, vape shops, hydro stores, brands and more. NUGL’s flexible web app has no geographic limitations and can rapidly connect cannabis companies, related vertical services and users. The NUGL iOS and Android app brings a powerful cannabis search tool within reach of anyone, anytime, anywhere with the ease of a smartphone.

For more information and updates, visit one of the links below.

Website: http://www.nugl.com/
Facebook: https://www.facebook.com/nuglapp/
Instagram: https://www.instagram.com/justnuglit/
Twitter: https://twitter.com/nuglapp/

LinkedIn: https://www.linkedin.com/company/nuglapp/

Newsletter: https://nugl.us16.list-manage.com/subscribe?u=219fe8bb6995a19827c9f36cb&id=dc46712578

Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include projections of matters that affect revenue, operating expenses or net earnings; projections of growth; and assumptions relating to the foregoing. Such forward-looking statements are generally qualified by terms such as: “plans”, “anticipates,” “expects,” “believes” or similar words of like kind. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or qualified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. These factors are discussed in greater detail in the company’s business plan and filings with the OTC Markets Group.

Contact Information:

Website: www.nugl.com
Email: info@nugl.com
Phone: (714) 383-9982

Investor Relations & Financial Media

info@integrityir.com

Toll Free: (888) 216-3595

www.IntegrityIR.com

Petroteq Energy 2018 Year-End Review

Sherman Oaks, California–(Newsfile Corp. – December 13, 2018) –  Petroteq Energy Inc. (TSXV: PQE) (OTC Pink: PQEFF) (FSE: PQCF) (“Petroteq” or the “Company“), a fully integrated oil and gas company with production assets in the Asphalt Ridge region of Vernal, Utah, is pleased to provide a 2018 year-end operations and strategic update:

Dear Shareholders,

As we begin to close out 2018, and 2019 fast approaches, I’d like to take this opportunity to reflect on Petroteq’s progress in 2018 and provide insight into our near-term strategy and goals for the Company. Developed specifically for our patented, environmentally friendly clean oil recovery technology and production process, our Vernal, Utah facility was successfully relocated, reconstructed and restarted earlier this year. The move, executed within only 8 months, allowed us to expand the facility’s capacity, currently designed to produce at a rate of 1,000 barrels per day (bpd).

Commodity Volatility Mitigation

We believe that the recent volatility of global commodity prices has been a cause for concern to conventional oil producers subject to high production costs. However, Petroteq’s state of the art technology and process, with production costs of only approximately US$30/barrel, significantly mitigates those concerns and supports healthy margins despite prevailing market conditions. Furthermore, upon receipt of the necessary capital, the Company intends to expand the Vernal facility beyond the current capacity of 1,000 bpd. We firmly believe that Petroteq is squarely on the right path to accessing and producing from the majority of Asphalt Ridge’s 87.495 million barrels of contingent resource, details of which are available in a report titled “Evaluation of Contingent Resources” from Chapman Petroleum Engineering, Ltd. dated May 31, 2018 (the “Chapman Report”). Such contingencies are stated below.

Share Consolidation Vote

Petroteq’s board recently brought the matter of a 1 for 10 consolidation of the Company’s common shares to a shareholder vote, a necessary corporate action for Petroteq in order to reach a minimum share price requirement for listing on the NASDAQ Capital Market. Shareholders overwhelmingly approved the measure, however, the board has resolved that the Company will not use a consolidation ratio beyond 1 for 5. The Company intends to engage a transparent and cautious methodology to the proposed NASDAQ listing with the belief that, given the recently achieved and the anticipated milestones, it may meet the requirements for a NASDAQ listing without corporate intervention. Acceptance for listing Company shares is subject to approval, in part, based on the Company’s ability to meet minimum listing requirements for the NASDAQ Capital Market. While Petroteq intends to satisfy all of the applicable listing criteria, no assurance can be given that its application will be approved.

Operational Growth

The Company continues to work towards a goal of running multiple operational facilities, with larger production capacities and expanded licensing opportunities for its technology, including the potential deployment of this technology for soil remediation and reclamation of environmental hydrocarbons. We will approach these other potential value-add projects through licensing, joint ventures and other such structures, always being focused on minimizing capital expenditures and maximizing the creation of shareholder value. In 2019, we will move the Vernal facility into Phase 2 of its lifecycle, during which we plan to increase production capacity from 1,000 bpd to 4,000 bpd by the end of the year. Civil construction of the additional process train will commence in the second quarter of the year, with the expansion estimated to come online by the third quarter. We will demonstrate an increased focus on production in the third quarter as the process trains ramp up to 4,000 bpd through tandem operations.

Commitment to Shareholder Value

As we execute on our strategy and share our vision for the future, we remain committed to achieving each of the Company’s deliverables and will keep our shareholders informed throughout. Our plan is designed to ensure we constantly strive to become a more focused and efficient company. As the Company grows, we will focus our asset base to achieve consistent, incremental production and will follow a disciplined capital allocation process with the intention of reducing our costs. We believe this approach will enhance our Company’s sustainability and returns for its shareholders.

At this critical juncture in Petroteq’s corporate development, I look forward to working alongside our board of directors, management and on-site operational teams as we execute our plan and strategy.

For a comprehensive view of our goals and direction, please visit our website: www.petroteq.energy

We will continue to communicate with our shareholders regularly and look forward to sharing new developments soon.

On behalf of everyone at Petroteq Energy, I would like to wish you all a safe and happy holiday and a prosperous and safe 2019.

Best regards,

David Sealock, CEO

About Petroteq Energy Inc.

Petroteq is a fully integrated oil and gas company focused on the development and implementation of a new proprietary technology for oil extraction. The Company has an environmentally safe and sustainable technology for the extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. Petroteq is engaged in the development and implementation of its patented environmentally friendly heavy oil processing and extraction technologies. Our proprietary process produces zero greenhouse gas, zero waste and requires no high temperatures. Petroteq is currently focused on developing its oil sands resources and expanding production capacity at its Asphalt Ridge heavy oil extraction facility located near Vernal, Utah. In addition, the Company, through its wholly owned subsidiary, PetroBLOQ, LLC, is seeking to develop the first blockchain based platform created exclusively for the supply chain needs of the oil & gas sector. For more information, visit www.Petroteq.energy and PetroBLOQ.com.

Forward-Looking Statements

Certain statements contained in this press release contain forward-looking statements within the meaning of the U.S. and Canadian securities laws. Words such as “may,” “would,” “could,” “should,” “potential,” “will,” “seek,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions as they relate to the Company, including: including the production capacity of the plant and when it may be achieved; completion of the consolidation; listing on Nasdaq; the Company having multiple facilities, larger production capacities, and licensing opportunities for its technology, including potentially using its technology for soil remediation and reclamation of environmental hydrocarbons; the structures used in any successful licensing opportunities; licensing opportunities creating shareholder value; the Company becoming a more efficient company with a stronger balance sheet; the Company achieving consistent production; the Company reducing costs; and the Company successfully developing blockchain technology for the oil and gas industry and the anticipated benefits of such technology, are intended to identify forward-looking information. Readers are cautioned that there is no certainty that it will be commercially viable to produce any portion of the resources. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, based on information available to the Company, and are subject to certain risks, uncertainties and assumptions. Material factors or assumptions were applied in providing forward-looking information, including: the contingencies in the Chapman Report being overcome; regulatory/stock exchange approval of the consolidation; the Company meeting all of the listing requirements of Nasdaq; Nasdaq approving the listing of the common shares, and PetroBLOQ successfully developing and implementing a blockchain-based supply chain management system. While forward-looking statements are based on data, assumptions and analyses that the Company believes are reasonable under the circumstances, whether actual results, performance or developments will meet the Company’s expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of the Company to differ materially from its expectations. Petroteq’s proprietary solvent based extraction technology is unproven to produce on a commercial basis at 1,000/bpd. Commercial production of 1,000/bpd at its existing plant is unproven and expansion at the existing plant or a new larger plant is subject to financing, development and testing to prove it is achievable and commercial. Certain of the “risk factors” that could cause actual results to differ materially from the Company’s forward-looking statements in this press release include, without limitation: uncertainties inherent in the estimation of resources including whether any reserves will ever be attributed to the Company’s properties; since the Company’s extraction technology is proprietary, not widely used in the industry, and has not been used in consistent commercial production, the Company’s bitumen resources are classified as a contingent resource, because they are not currently considered to be commercially recoverable; full scale commercial production may engender public opposition; the Company cannot be certain that the bitumen resources will be economically producible and thus cannot be classified as proved or probable reserves in accordance with applicable securities laws; PetroBLOQ not having the expertise and/or funds necessary to develop and implement a blockchain-based supply chain management system; PetroBLOQ not being able to develop the blockchain technology to completion; blockchain technology not being adopted by the oil and gas industry; changes in laws or regulations; the ability to implement business strategies or to pursue business opportunities, whether for economic or other reasons; status of the world oil markets, oil prices and price volatility; oil pricing; state of capital markets and ability by the Company to raise capital; litigation; the commercial and economic viability of the Company’s oil sands hydrocarbon extraction technology, and other proprietary technologies developed or licensed by the Company or its subsidiaries, which are of experimental nature and have not been used at full capacity for an extended period of time; reliance on suppliers, contractors, consultants and key personnel; the ability of the Company to maintain its mineral lease holdings; potential failure of the Company’s business plans or model; the nature of oil and gas production and oil sands mining, extraction and production; uncertainties in exploration and drilling for oil, gas and other hydrocarbon-bearing substances; unanticipated costs and expenses, availability of financing and other capital; potential damage to or destruction of property, loss of life and environmental damage; risks associated with compliance with environmental protection laws and regulations; uninsurable or uninsured risks; potential conflicts of interest of officers and directors; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in the Company’s disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com.

Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Pursuant to the Chapman Report, the following is a summary of contingencies and project risk related to the Company’s 93.4 million barrels of contingent resource, listed in order of importance: (i) Verification of actual full scale processing and operating costs. Although the Company has developed detailed estimates of these costs by operating the pilot plant, they will need to implement the full scale project in order to know these costs with certainty. Chapman has estimated a 90% probability that operating costs will be in the ranges estimated in the monte carlo simulation, as documented in our September 1, 2016 report. The simulation indicates that there is a 97.5% likelihood of having an economic project if costs are in those ranges. Therefore, the probability of this contingency being overcome (i.e. operating costs are in the range estimated by Chapman) is estimated at 88%; (ii) Mining costs will be similar on all Company lands. Detailed mining cost estimates have only been prepared for the first 12.8 MMSTB of bitumen to be mined, but it is anticipated that the bitumen volumes could be scaled up at a similar cost. The probability of this contingency being overcome (i.e. all actual mining costs being in line with initial estimates) is estimated at 95%; and (iii) Regulatory permission will be granted for all future stages. This is seen as very likely, and there are no major regulatory hurdles remaining to overcome. However, there is potential for public opposition to a project of this nature. The probability of this contingency being overcome (i.e. all future regulatory approvals being granted) is estimated at 98%. Chapman has estimated that it is 81.9% likely that all of the above contingencies will be overcome.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT INFORMATION:

Petroteq Energy Inc.
Alex Blyumkin
Executive Chairman & Founder
(800) 979-1897

Wolverine Provides Update on CHALK/DZI Litigation

Vancouver, British Columbia–(Newsfile Corp. – December 13, 2018) – Wolverine Technologies Corp. (OTC Pink: WOLV) today provided the following update on the Chalk/DZI litigation.

Dr. Chalk continues to pursue his lawsuit against Decision-Zone Inc. (“DZI”), Rajeev Bhargava, and Nalini Bhargava for, among other things, oppression of him in his capacity as an officer and shareholder of DZI (the “Oppression Action”). As set out in the Statement of Claim, central to this oppression has been the actions by the Defendants to deny Dr. Chalk access to documents that would reveal the state of affairs of DZI, and the actions of Rajeev and Nalini Bhargava in doing so. This includes the apparent incorporation, without the full knowledge or oversight of the DZI Board of Directors, of a US-based subsidiary and licensing or assignment of rights of DZI technology to it. This refusal to provide documentation has now extended to the litigation itself, with the defendants having refused to list or produce whole categories of relevant and material documents despite their obligation to do so. Counsel for Dr. Chalk will shortly be setting down dates for the examination for discovery of Rajeev Bhargava in the Oppression Action with the goal of compelling production of relevant and material documents in the litigation, as well as the larger goal of uncovering the true state of affairs of DZI.

On Behalf of the Board

Richard Haderer
CEO

For further information please contact:

Corporate Communications (778) 297-4409
investor@wolverinetechnologiescorp.com
http://www.wolverinetechnologiescorp.com

Investor Relations
Mr. Dale Shirley
Big Reach Media, Inc.
Phone: (780) 632-6963
Mobile: (780) 964-4732
dale@bigreachmedia.com
http://www.bigreachmedia.com/

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, statements regarding the Chalk/Decision-Zone litigation.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with technology development and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

CVR Medical Provides TUV Safety Testing Update

Denver, North Carolina–(Newsfile Corp. – December 13, 2018) – CVR Medical Corp. (TSXV: CVM) (OTCQB: CRRVF) (“CVR Medical”), a Canadian listed and US based healthcare company in the medical device sector announces that its patented, disruptive Carotid Stenotic Scan (CSS) has passed the IEC 60601-1-2 edition 4, General Requirements for Basic Safety and Essential Performance – Electromagnetic Disturbances conducted by TUV Rheinland of North America. TUV Rheinland of North America, is one of the leading providers of product safety certifications worldwide, covering an assortment of items such as medical devices, home appliances, audio/video products, medical products, textiles and telecommunication equipment. This testing is required for the CSS’s subsequent De Novo submission to the FDA for US market clearance and will show that the device is compliant with all IEC 60601-1-2 EMC requirements. The International Electrotechnical Commission (IEC), based in Geneva, Switzerland, publishes the 60601 series of technical standards that allow medical device developers to demonstrate the safety and essential performance of their medical equipment. Upon completion of EMC testing, TUV North America started IEC 60601-1 safety testing which includes, software and hardware validation, fire and electrical safety and mechanical failure. As announced, CVR’s previous guidance relating to FDA submission remains unchanged for Q1 2019.

In speaking to CVR’s VP of Program Management & Product Development, Lewis Crenshaw, the TUV engineer stated “CVR’s team did a tremendous job preparing documentation and hardware for IEC 60601-1-2 EMC safety testing. This allowed the TUV team to quickly and efficiently tackle the testing, review technical documents and draft and sign the EMC test report during the busiest time of our year.”

Tony Robinson, CVR Medical’s Chief Operating Officer stated, “This represents one of the final hurdles standing between CVR and the FDA submission that we have been working so diligently towards. Many companies are significantly delayed by requirements such as EMC, but thanks to the thoroughness of the CVR engineering team and open dialogue which TUV provided, we have been able to maintain our momentum toward our objectives. Working with TUV has been the epitome of efficiency and effectiveness, even during this extraordinarily busy time. We know that when our CSS device is placed into the clinical setting we are holding ourselves to the industry’s highest standard of electrical safety.”

About CVR Medical

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its disruptive, proprietary Carotid Stenotic Scan (CSS). The CSS device is a diagnostic tool that encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS is a patented device designed to detect and measure carotid arterial stenosis. CVR is currently in pivotal clinical trials in preparation for its planned submission to the FDA. CVR is led by an experienced and proven team of professionals with extensive healthcare, medical device, international expansion, regulatory and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM. Additional information regarding the Company can be found in our recent filings with the SEDAR as well as the information maintained on our website at www.cvrmed.com

ON BEHALF OF THE BOARD:
(signed) “Peter Bakema”
CEO, President & Chairman

For further information contact:
Peter Bakema, CEO, President and Chairman
Email: info@cvrmed.com
or
Marc S. Lubow
Vice President Capital Markets, Director Investor Relations
904-923-4037
marclubow@cvrmed.com

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.